KR860000931B1 - 궤양 치료제인 2-구아니디노-4-(2-치환된-아미노-4-이미다졸릴)-티아졸의 제조방법 - Google Patents

궤양 치료제인 2-구아니디노-4-(2-치환된-아미노-4-이미다졸릴)-티아졸의 제조방법 Download PDF

Info

Publication number
KR860000931B1
KR860000931B1 KR1019830001962A KR830001962A KR860000931B1 KR 860000931 B1 KR860000931 B1 KR 860000931B1 KR 1019830001962 A KR1019830001962 A KR 1019830001962A KR 830001962 A KR830001962 A KR 830001962A KR 860000931 B1 KR860000931 B1 KR 860000931B1
Authority
KR
South Korea
Prior art keywords
formula
alkyl
compound
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019830001962A
Other languages
English (en)
Korean (ko)
Other versions
KR840004745A (ko
Inventor
로렌스 라마티나 존
앤드루 리핀스키 크리스토퍼
Original Assignee
화이자 인코포레이티드
윌리암 데이비스 휸
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드, 윌리암 데이비스 휸 filed Critical 화이자 인코포레이티드
Publication of KR840004745A publication Critical patent/KR840004745A/ko
Application granted granted Critical
Publication of KR860000931B1 publication Critical patent/KR860000931B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Lubricants (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1019830001962A 1982-05-10 1983-05-09 궤양 치료제인 2-구아니디노-4-(2-치환된-아미노-4-이미다졸릴)-티아졸의 제조방법 Expired KR860000931B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US376,486 1982-05-10
US06/376,486 US4435396A (en) 1982-05-10 1982-05-10 Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor

Publications (2)

Publication Number Publication Date
KR840004745A KR840004745A (ko) 1984-10-24
KR860000931B1 true KR860000931B1 (ko) 1986-07-19

Family

ID=23485203

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830001962A Expired KR860000931B1 (ko) 1982-05-10 1983-05-09 궤양 치료제인 2-구아니디노-4-(2-치환된-아미노-4-이미다졸릴)-티아졸의 제조방법

Country Status (26)

Country Link
US (1) US4435396A (https=)
EP (1) EP0094191B1 (https=)
JP (1) JPS58206588A (https=)
KR (1) KR860000931B1 (https=)
AT (1) ATE33649T1 (https=)
AU (2) AU539244B2 (https=)
CA (1) CA1201120A (https=)
CS (1) CS252461B2 (https=)
DD (1) DD209828A5 (https=)
DE (1) DE3376322D1 (https=)
DK (1) DK163829B (https=)
EG (1) EG17029A (https=)
ES (1) ES522223A0 (https=)
FI (1) FI78481C (https=)
GR (1) GR79279B (https=)
GT (1) GT198302123A (https=)
HU (2) HU190899B (https=)
IE (1) IE55229B1 (https=)
IL (1) IL68630A (https=)
NO (1) NO159932C (https=)
NZ (1) NZ204158A (https=)
PL (1) PL141199B1 (https=)
PT (1) PT76662B (https=)
SU (1) SU1195907A3 (https=)
YU (1) YU42857B (https=)
ZA (1) ZA833286B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) * 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4673677A (en) * 1983-10-03 1987-06-16 Pfizer Inc. Method for treatment of gastrointestinal disorders
US4560690A (en) * 1984-04-30 1985-12-24 Pfizer Inc. 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents
US4636498A (en) * 1984-10-11 1987-01-13 Pfizer Inc. Formulation of antiinflammatory drugs
US4632993A (en) * 1984-10-11 1986-12-30 Pfizer Inc. Process for making 2-guanidino-4-(2-methyl-4-imidazolyl) thiazole dihydrobromide
WO1986003203A1 (fr) * 1984-11-22 1986-06-05 Yoshitomi Pharmaceutical Industries, Ltd. Derives de thienylthiazole
US4814341A (en) * 1986-08-26 1989-03-21 Reiter Lawrence A 2-guanidino-4-(2-furyl) thiazoles as antiulcer agents
ATE66477T1 (de) * 1986-08-29 1991-09-15 Pfizer 2-guanidino-4-aryl-thiazole fuer die behandlung von peptischen geschwueren.
EP0269239B1 (en) * 1986-10-29 1994-06-08 Pfizer Inc. Processes for 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and the crystalline dihydrochloride trihydrate thereof
WO1994028898A1 (en) * 1993-06-15 1994-12-22 Pfizer Inc. H2-antagonists as immune stimulants in bacterial infections of cattle or swine
US8536185B2 (en) * 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US20230349922A1 (en) 2020-08-11 2023-11-02 Université De Strasbourg H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519637A (en) 1966-12-06 1970-07-07 Hoffmann La Roche 1-(4-thiazolylmethyl)nitroimidazole derivatives
DE2142585A1 (de) * 1971-08-20 1973-02-22 Schering Ag 2-(5-nitro-2-thiazolyl)-benzimidazole
FR2284601A1 (fr) * 1974-09-10 1976-04-09 Inst Francais Du Petrole Composes guanidino-heterocycliques alkyles, leur preparation et leur utilisation comme additifs pour carburants et lubrifiants
US4220654A (en) 1979-06-04 1980-09-02 Merck & Co., Inc. Cyclic imidazole cyanoguanidines
US4374843A (en) 1980-10-14 1983-02-22 Pfizer Inc. 2-Guanidino-4-heteroarylthiazoles

Also Published As

Publication number Publication date
CS318483A2 (en) 1987-02-12
FI831595L (fi) 1983-11-11
IL68630A0 (en) 1983-09-30
EP0094191B1 (en) 1988-04-20
DK163829B (da) 1992-04-06
DE3376322D1 (en) 1988-05-26
JPS58206588A (ja) 1983-12-01
AU1436383A (en) 1983-11-17
ES8407045A1 (es) 1984-08-16
FI78481C (fi) 1989-08-10
IE55229B1 (en) 1990-07-04
FI78481B (fi) 1989-04-28
PL241840A1 (en) 1985-01-16
PL141199B1 (en) 1987-07-31
ZA833286B (en) 1984-12-24
DK205883A (da) 1983-11-11
DK205883D0 (da) 1983-05-09
CS252461B2 (en) 1987-09-17
PT76662B (en) 1986-04-16
FI831595A0 (fi) 1983-05-09
NO831632L (no) 1983-11-11
IE831061L (en) 1983-11-10
NO159932B (no) 1988-11-14
AU3081584A (en) 1984-11-08
YU99683A (en) 1986-02-28
EG17029A (en) 1992-06-30
GR79279B (https=) 1984-10-22
SU1195907A3 (ru) 1985-11-30
YU42857B (en) 1988-12-31
HU190899B (en) 1986-12-28
GT198302123A (es) 1984-10-27
US4435396A (en) 1984-03-06
IL68630A (en) 1987-03-31
AU539244B2 (en) 1984-09-20
KR840004745A (ko) 1984-10-24
NZ204158A (en) 1986-05-09
EP0094191A1 (en) 1983-11-16
DD209828A5 (de) 1984-05-23
CA1201120A (en) 1986-02-25
PT76662A (en) 1983-06-01
ES522223A0 (es) 1984-08-16
HU196377B (en) 1988-11-28
ATE33649T1 (de) 1988-05-15
NO159932C (no) 1989-02-22
AU566755B2 (en) 1987-10-29

Similar Documents

Publication Publication Date Title
EP0161841B1 (en) 2-(n-substituteguanidino)-4-hetero-arylthiazole antiulcer agents
KR860000931B1 (ko) 궤양 치료제인 2-구아니디노-4-(2-치환된-아미노-4-이미다졸릴)-티아졸의 제조방법
KR850001858B1 (ko) 2-구아니디노-4-헤테로아릴티아졸의 제조 방법
JPH0233031B2 (https=)
US4490527A (en) Benzo-fused heterocyclic anti-ulcer agents
DE3035086C2 (https=)
FI72974C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara imidazolylpyridiner.
DK168763B1 (da) Heterocykliske derivater, farmaceutiske præparater indeholdende disse, deres anvendelse ved behandlingen af histaminformidlede tilstande i hjernen samt fremgangsmåder til deres fremstilling
EP0074229B1 (en) Triazole gastric anti-secretory agents
US4461901A (en) Pyridyl containing 1,2-benzisothiazole-3-amine derivatives
EP0223512B1 (en) 2-pyridylacetic acid derivative, preparation process thereof and pharmaceutical composition containing the same
HU191496B (en) Process for producing derivates 2-guanidino-4thiazolyl-thiazoles
US4452987A (en) Haloacetyl imidazoles
GB2053910A (en) Pyridylaminotriazole therapeutic agents
JPH0428697B2 (https=)
JPS63230670A (ja) 置換ピリジル酢酸誘導体
US4591595A (en) 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis
KR870000924B1 (ko) 2-(n-치환된 구아니디노)-4-헤테로아릴티아졸의 제조방법
FI73990C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva imidazolylpyridiner.
JPS58170779A (ja) ピリジン誘導体
JPH034068B2 (https=)
CS235969B2 (cs) Způsob výroby 2-guanidino-4-thiazolylthiazolů
JPH0544470B2 (https=)
JPH01265024A (ja) ２―ピリジル酢酸誘導体およびそれを含む医薬

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 19910513

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19920720

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19920720

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000